Haemonetics Corp HAE

$118.51 +2.35 (2.02%)

Valuation

Market cap
5,284,932,000
Revenue TTM
$1,334,030,000
Net income TTM
$97,310,000
PE ratio
23.38
Forward PE
22.13
Profit margin
7.29%
Debt to equity
1.40

Trading

Volume
777,300
Avg volume
704,056
Day's range
$115.49 – $119.20
Shares out
45,497,000
Stochastic %K
36%
Beta
0.61
Analysts
Strong Sell
Price target
$124.36

Price

Company profile

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information tec...

Show more

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.

Industry
Medical Devices
Sector
Healthcare
Phone
781 848 7100
Website
https://www.haemonetics.com
Address
125 Summer Street, Boston, United States

Latest news

Stocktwits

RenkoTradingSystem Oct 21, 9:40 PM
I'm passing on $HAE because it has 3 red bricks.
0 replies
RenkoTradingSystem Oct 21, 2:04 PM
$HAE Since I mentioned position sizing and risk management, this is how it works: POSITION SIZING & RISK MANAGEMENT Example: Capital: $50,000 Maximum simultaneous trades: 6 Maximum risk per trade: 0.75% of total capital Maximum loss per trade: $50,000 × 0.0075 = $375 Position size is determined by the distance to the stop-loss. Position Size Formula Position Size = Risk ÷ Stop Distance Example: If the stop distance is 5%: $375 ÷ 0.05 = $7,500
0 replies
RenkoTradingSystem Oct 21, 1:54 PM
$HAE I'm still waiting for two green bricks. So far it has been a perfect reset with the StochRSI going below 0.2. My normal Max Risk per trade is 0.75% of my total bankroll, but because of all the previous Green Bricks, I will adjust my Max Risk in half (0.375%)
0 replies
RenkoTradingSystem Oct 20, 1:47 PM
$HAE I'm waiting for two green bricks.
0 replies
filecrux Oct 19, 8:27 PM
$HAE, maker of plasma-collection and hospital blood and vascular-closure devices, won FDA approval for PerQseal Elite, the large-bore closure patch it bought with Vivasure in Jan 2026 for €100M upfront plus up to €85M in milestones. Interventional Technologies (vascular closure, sensor-guided, esophageal) had $59.9M of $339.4M sales, qtr to 6/27/26; HAE ~$5.40B at $118.66 (16:00 ET Oct 19, 2026). Opens U.S. sales after a trial with 0% major complications, but pre-deal Vivasure revenue was "nominal." Next: TCT data end of October; Q2 call in November.
0 replies
Rayvio_News_Filter Oct 19, 8:15 PM
$HAE 🏥 Haemonetics Corporation received FDA approval for its PerQseal Elite Vascular Closure System. Selected from hundreds of headlines
0 replies
RenkoTradingSystem Oct 18, 10:57 AM
$HAE System Health Check: • SPY Gatekeeper (Weekly RSI 51–85): 58.11 - PASS • SCTR Threshold (≥ 65.0): 99.1 - PASS • Weekly Renko Trend: Active green brick ($118.28) - PASS • Weekly EMA(20): Above rising EMA ($118.28 > $109.22) - PASS • Weekly RSI(14): 76.38 - PASS • 195-Min Setup: Pullback in progress (2nd red brick, StochRSI at 0.145) - DEVELOPING • Earnings Date: Nov 5, 2026 (~18 days away) - PASS Status: QUALIFIED / TOP WATCHLIST Technical Summary: HAE features a 99.1 SCTR, strong weekly uptrend, and robust momentum. On the 195-minute chart, it is pulling back (2 red bricks down from $121.83) with StochRSI fully reset at 0.145. With earnings providing a clean 18-day runway, HAE meets all criteria and awaits a confirmed 2nd green brick trigger.
0 replies
Bucephale13 Oct 17, 5:32 PM
$HAE 🍾🍾🍾🍾🍾🍾
0 replies